» Articles » PMID: 35228427

Atypical, Levetiracetam-induced Hypersensitivity Syndrome Complicated by Fulminant Liver Failure in a Patient Undergoing Hemodialysis

Overview
Journal Intern Med
Specialty General Medicine
Date 2022 Mar 1
PMID 35228427
Authors
Affiliations
Soon will be listed here.
Abstract

A 59-year-old man undergoing hemodialysis was administered levetiracetam, after which he developed a systemic rash, high fever, severe liver dysfunction, and leukocytopenia with reactivation of human herpes virus 6. Atypical drug-induced hypersensitivity (DIHS) was diagnosed, and prednisolone was administered at 60 mg/day. However, liver failure rapidly progressed, and the patient died 12 days following treatment. Despite the rarity of DIHS with concomitant fulminant liver failure from levetiracetam and sufficient clearance thereof by hemodialysis, our case suggests that this syndrome may still ensue, resulting in mortality, even in hemodialysis patients. Although no treatment has yet been established, strict monitoring and aggressive treatment may be required.

Citing Articles

Fatal outcome related to drug reaction with eosinophilia and systemic symptoms: a disproportionality analysis of FAERS database and a systematic review of cases.

Liang C, An P, Zhang Y, Liu X, Zhang B Front Immunol. 2024; 15:1490334.

PMID: 39737180 PMC: 11683082. DOI: 10.3389/fimmu.2024.1490334.

References
1.
Lee T, Lee Y, Yoon S, Kim S, Bae Y, Kwon H . Characteristics of liver injury in drug-induced systemic hypersensitivity reactions. J Am Acad Dermatol. 2013; 69(3):407-15. DOI: 10.1016/j.jaad.2013.03.024. View

2.
Shiue H, Taylor M, Sands K . Comparison of Levetiracetam Dosing Regimens in End-Stage Renal Disease Patients Undergoing Intermittent Hemodialysis. Ann Pharmacother. 2017; 51(10):862-865. DOI: 10.1177/1060028017713294. View

3.
Shiohara T, Mizukawa Y . Drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): An update in 2019. Allergol Int. 2019; 68(3):301-308. DOI: 10.1016/j.alit.2019.03.006. View

4.
Cabanas R, Ramirez E, Sendagorta E, Alamar R, Barranco R, Blanca-Lopez N . Spanish Guidelines for Diagnosis, Management, Treatment, and Prevention of DRESS Syndrome. J Investig Allergol Clin Immunol. 2020; 30(4):229-253. DOI: 10.18176/jiaci.0480. View

5.
Kardaun S, Sidoroff A, Valeyrie-Allanore L, Halevy S, Davidovici B, Mockenhaupt M . Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?. Br J Dermatol. 2007; 156(3):609-11. DOI: 10.1111/j.1365-2133.2006.07704.x. View